Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000188943 | SCV000242574 | likely benign | not provided | 2021-05-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000814902 | SCV000955339 | likely benign | Early infantile epileptic encephalopathy with suppression bursts | 2024-10-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001328554 | SCV001519699 | uncertain significance | Migraine, familial hemiplegic, 3 | 2019-08-08 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Ambry Genetics | RCV002517011 | SCV003756891 | uncertain significance | Inborn genetic diseases | 2021-05-01 | criteria provided, single submitter | clinical testing | The c.4162G>A (p.E1388K) alteration is located in exon 21 (coding exon 21) of the SCN1A gene. This alteration results from a G to A substitution at nucleotide position 4162, causing the glutamic acid (E) at amino acid position 1388 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |